Skip to Content
Søg Menu
Velkommen til lungecancer

Få de seneste artikler og MEDtalks om lungecancer

Seneste nyt om lungecancer

Danish and Nordic Lung Cancer Insights – October Update

  • / Jan Andreasen / Amanda Feldballe Bernholm
Katharina Leuchte

ESMO 2025: High-Intensity Interval Training Promotes Immune Responses in mNSCLC Patients

/ Katharina Leuchte
ESMO25Lungecancer Play the Video
Pasi Jänne

New Class of Medicines Emerge as Potential Therapies in MTAP-Deleted NSCLC

/ Pasi Jänne
WCLC25NSCLCLungecancer Play the Video
Michael Stenger

WCLC 2025: Lung Cancer Screening and Early Results from the Danish PLUS Trial

/ Michael Stenger
WCLC25Lungecancer Play the Video

Lung Cancer Highlights

Lung Cancer Insights: What’s New in the Field – October Update

/ Jan Andreasen / Amanda Feldballe Bernholm
lung cancer-highlightsLungecancer

Lung Cancer Insights: What’s New in the Field

/ Jan Andreasen / Amanda Feldballe Bernholm
lung cancer-highlightsLungecancer

MEDtalks

Maria Silvoniemi

Clinical Dilemmas in the Management of NSCLC Without Driver Mutations

/ Maria Silvoniemi
NSCLCLungecancer Play the Video
Edyta Maria Urbanska

Behandling af patienter med lungecancer og positiv for NTRK-fusioner

/ Edyta Maria Urbanska
Lungecancer Play the Video
Luis Paz-Ares

ASCO 2025: Lurbinectedin–Atezolizumab Improves Survival in SCLC

/ Luis Paz-Ares
ASCO25Lungecancer Play the Video
Odd Terje Brustugun

Perspektiver på behandlingsvalg ved NSCLC uten drivermutasjoner

/ Odd Terje Brustugun
Lungecancer Play the Video
Edyta Maria Urbanska

Amivantamab + lazartinib i 1.-linje øger overlevelsen ved avanceret EGFR muteret NSCLC vs osimertinib

/ Edyta Maria Urbanska
Lungecancer Play the Video
Miriam Grønberg

Treatment Timing Impacts Survival in Limited Stage Small Cell Lung Cancer

/ Miriam Grønberg
Lungecancer Play the Video
Hent flere

Artikler

Behov for mere viden om behandling af NSCLC med immunterapi uden driver mutationer

/ Julie Stougaard / Jan Andreasen
NSCLCLungecancer

Nyt behandlingsgennembrud for EGFR-muteret lungekræft

/ Seppo W. Langer
NSCLCLungecancer

New Data Support Osimertinib as a Backbone Treatment for EGFRm Advanced NSCLC

/ Jan Andreasen
WCLC25NSCLCLungecancer

Amivantamab + Lazertinib in EGFR-Mutated Advanced NSCLC: PALOMA-2 Update

/ Jan Andreasen
WCLC25NSCLCLungecancer

First-Line NSCLC Without Driver Mutations: Practice, Gaps, and Costs

/ Ronny Öhman / Jan Andreasen
NSCLCLungecancer

Jens Benns møde med Heine var skelsættende for valget af lungeonkologien

/ Jens Benn Sørensen / Amanda Feldballe Bernholm
Lungecancer
Back to top